Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 29, 2015		Mar. 30, 2014
Restructuring Reserve [Roll Forward]
Balance, December 31, 2014	$ 1,166	[1]
Provision	42	[2]	40	[2]
Utilization and other	(162)	[3]
Balance, March 29, 2015	1,046	[4]
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2014	1,114	[1]
Provision	31
Utilization and other	(127)	[3]
Balance, March 29, 2015	1,019	[4]
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2014	0	[1]
Provision	6
Utilization and other	(6)	[3]
Balance, March 29, 2015	0	[4]
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2014	52	[1]
Provision	6
Utilization and other	(30)	[3]
Balance, March 29, 2015	$ 28	[4]

[1] Included in Other current liabilities ($735 million) and Other noncurrent liabilities ($431 million).

[2] In the three months ended March 29, 2015, Employee terminations represent the expected reduction of the workforce by approximately 200 employees, mainly in manufacturing and sales.The restructuring charges for the three months ended March 29, 2015 are associated with the following:•the Global Innovative Pharmaceutical segment (GIP) ($12 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($13 million); the Global Established Pharmaceutical segment (GEP) ($10 million); Worldwide Research and Development and Medical ($12 million); manufacturing operations ($22 million income); and Corporate ($18 million).The restructuring charges for the three months ended March 30, 2014 are associated with the following:•the Global Innovative Pharmaceutical segment (GIP) ($2 million); the Global Established Pharmaceutical segment (GEP) ($7 million); Worldwide Research and Development and Medical ($1 million); manufacturing operations ($26 million); and Corporate ($4 million).

[3] Includes adjustments for foreign currency translation.

[4] Included in Other current liabilities ($648 million) and Other noncurrent liabilities ($398 million).